We describe the production of eight monoclonal antibodies reactive with human immunodeficiency virus type 1 reverse transcriptase (RT) by immunization of mice with purified recombinant RT. These antibodies were found to react with one or the other of two regions of the enzyme and were found to be useful in immunoaffinity purification of large amounts of the enzyme. One epitope located at the C terminus of the enzyme was of particular interest, since it was present in only the larger, 66-kilodalton (kDa) RT RT consists of 66-and 51-kilodalton (kDa) viral polypeptides (4, 6). These two polypeptides have a common aminoterminus (6, 14), which has led di Marzo Veronese et al. to suggest that the 51-kDa polypeptide is derived from the 66-kDa polypeptide by cleavage near the carboxy terminus. In our laboratory, the RT gene (LAV strain) has been cloned and the 66-kDa polypeptide has been expressed to high levels in Escherichia coli. These experiments demonstrated that the 66-kDa polypeptide possesses authentic RT activity (11). The aim of this study was to use RT from E. coli to prepare a specific antibody to the protein and to use the antibody to purify and characterize it. The 66-kDa expressed polypeptide purified by a combination of DNA-cellulose and anion-exchange chromatographies (11) was used to immunize mice to isolate MAbs.
of the enzyme; however, even the 51-kDa enzyme component had demonstrable activity.
Reverse transcriptase (RT) of human immunodeficiency virus (HIV), the etiological agent of acquired immune deficiency syndrome, is an enzyme of central importance in the replication of this virus. The enzyme is known to be a highly immunogenic protein. Thus, a high percentage of HIVpositive human sera have significant levels of anti-RT antibodies (5, 13) , and monoclonal antibodies (MAbs) to the enzyme have been raised in mice primed with detergent lysates of purified HIV. Such antibodies have demonstrated that RT consists of 66-and 51-kilodalton (kDa) viral polypeptides (4, 6) . These two polypeptides have a common aminoterminus (6, 14) , which has led di Marzo Veronese et al. to suggest that the 51-kDa polypeptide is derived from the 66-kDa polypeptide by cleavage near the carboxy terminus. In our laboratory, the RT gene (LAV strain) has been cloned and the 66-kDa polypeptide has been expressed to high levels in Escherichia coli. These experiments demonstrated that the 66-kDa polypeptide possesses authentic RT activity (11) . The aim of this study was to use RT from E. coli to prepare a specific antibody to the protein and to use the antibody to purify and characterize it. The 66-kDa expressed polypeptide purified by a combination of DNA-cellulose and anion-exchange chromatographies (11) was used to immunize mice to isolate MAbs.
Mapping of the antibody epitopes was done by making stop codons in the RT gene expression casette by sitespecific mutagenesis, creating mutants with truncated C termini which were also of value in the study of the RT activity of the polypeptides. During the course of this study, Hansen et al. (8) , using a MAb raised against the carboxyterminal portion of the 66-kDa polypeptide, presented evidence claiming that the 51-kDa polypeptide is processed from the 66-kDa polypeptide by generation of a 15-kDa polypeptide that has RNase H activity and is derived from the C terminus of the 66-kDa polypeptide and that the 51-kDa polypeptide lacks RT (1) was used to prepare hybridomas. The fusion was performed with 50% polyethylene glycol by using the mouse myeloma cell line P3/NS-1/1-Ag4-1 (NS-1) (9), and the fused cells were plated out into 24-well Linbro plates. The supernatant fluids from these wells were screened for anti-RT antibodies by enzyme-linked immunosorbent assay (ELISA) as described by Banks et al. (1) , with purified RT as the antigen. Hybridomas from positive wells were isolated, cultured, and again tested by ELISA, and positive cultures were tested by Western blot analysis (2) against bacterial extracts of RT. Positive clones were further cloned by limiting dilution, and these clones were used to prepare ascitic fluid as described by Banks et al. (1) . The MAbs obtained were subtyped by using anti-mouse immunoglobulin G (IgG) subtype sera as the second antibody in ELISAs with purified RT as the antigen.
Neutralization of RT activity. RT assays were performed as described by Larder et (7) and coupled to thyroglobulin by using glutaraldehyde (15) . ELISAs were performed as previously described (1) Immunoadsorbent chromatography. The MAb was partially purified from ascitic fluid by precipitation with 50% ammonium sulfate, followed by DEAE-cellulose chromatography. From 5 to 10 mg of the antibody was coupled to each gram of CNBr-activated Sepharose 4B (Pharmacia Inc., Piscataway, N.J.) as directed by the manufacturer. Bacterial extracts of RT were prepared by high-salt fractionation (11) and applied to the column in 50 mM diethylamine buffer (pH 8.8) with 0.1 M sodium chloride. After the column was washed with buffer, the RT was eluted with 50% ethylene glycol in diethylamine buffer (pH 8.8). The ethylene glycol was subsequently removed by a G25 column run in series. Fractions were assayed for RT activity and analyzed on polyacrylamide gels, and the A280 was read. The specific activity of the purified enzyme was determined (1 U of enzyme catalyzes the incorporation of 1 nmol of dTMP in 10 min at 37°C). Further Western blots were performed with high levels of purified bacterially expressed RT, which have been found to contain low levels of a 51-kDa polypeptide on stained gels (Fig. 2B ). The blots revealed that seven of the MAbs reacted RESULTS Isolation of MAbs to purified HIV RT. Mice were immunized as described in Materials and Methods, and their sera were screened for anti-RT antibodies by Western blotting (Fig. 1) . Two mice showed a strong reaction to the 66-kDa RT polypeptide present in bacterial extracts and a slight reaction to some E. coli proteins. These two mice were therefore used to prepare hybridomas. Eight hybridomas secreting RT MAbs were isolated. The MAbs reacted with RT in both ELISAs and Western blots with either supernatant or ascitic fluid.
Characterization of the eight MAbs. with both the 66-and 51-kDa polypeptides and thus confirmed that this 51-kDa polypeptide is derived from the 66-kDa polypeptide. With RTMAb6, a ladder of polypeptides between 66 and 51 kDa was seen. These polypeptides appear to be derived from the 66-kDa polypeptide. With RTMAb8, only the 66-kDa polypeptide reacted, which suggests that the 51-kDa polypeptide seen in viral and bacterial extracts is the same polypeptide.
Purification of RT from crude bacterial extracts with immunoadsorbent chromatography. To obtain large amounts of recombinant RT, we wished to use affinity chromatography with a MAb-based immunoadsorbent. On the basis of the Western blotting results, RTMAb8, which is 66-kD polypeptide specific, was chosen for immunoaffinity purification of the 66-kDa polypeptide. For purification of mutant polypeptides which do not bind to RTMAb8, a second MAb, RTMAb3, was selected. The results from a typical purification run for the 66-kDa protein are shown in Fig. 3 . By this method, considerable concentration and purification of the 66-kDa polypeptide were achieved, giving an enzyme with a specific activity of 1,000 to 4,000 U/mg. Similar results were obtained with the 51-kDa polypeptide expressed with mutant CTRT1 (see Table 3 ), giving an enzyme with a specific activity of 50 U/mg. Epitope mapping of RT MAbs 1 to 8. (i) Mapping with CNBr fragments of purified RT. The RT polypeptide contains five methionine residues which would be predicted to be cleaved by CNBr (Fig. 4, diagram) . Two of these residues are very close to the N terminus, and the other three are within the N-terminal half of the molecule. Complete fragmentation should give one major band at 39 kDa containing the C terminus plus smaller fragments derived from the N terminus.
The Western blots with MAbs 1 to 8 (Fig. 4) revealed that all eight of the MAbs reacted with the 39-kDa fragment and therefore provided good evidence that none maps near the N terminus of the molecule. However, since cleavage was not complete, a second band at 44 kDa arising from cleavage at Met-184 only also reacted with all of the MAbs. Further cleavage products were more difficult to identify; some probably arose from similar cleavage of the 51-kDa polypeptide also present in the starting material, and others probably arose from further, nonspecific breakdown. The strongly reactive lower band (RT MAbs 3 to 6) at approximately 29 kDa may be derived from the 51-kDa polypeptide by cleavage at Met-184.
(ii) Mapping with C-terminally truncated mutants. (a) Epitope mapping of RTMAb 8. If the 51-kDa polypeptide is derived from the 66-kDa polypeptide by cleavage of approximately 130 amino acids from the C terminus, then the reaction of RTMAb8 with only the 66-kDa polypeptide suggests that the epitope lies within these 130 amino acids at the C terminus. To confirm this, a previously prepared (11) deletion mutant, mpRT5, which removed the C-terminal domain (amino acids 431 to 562) by deleting a KpnI fragment from the DNA encoding the RT was used. The 53-kDa induced with isopropyl--D-thiogalactopyranoside (15 h), and extracts were prepared and run on gels for staining and blotting. Five microliters of each was taken for assays of RT activity with poly(rA)-oligo(dT) as the primer template.
In this assay system, 5KcPolASF' cells give no detectable polymerase activity (<200 cpm), allowing accurate determination of mutant RT activity. aa, Amino acids.
polypeptide expressed in E. coli with this construct did not react with RTMAb8. Therefore, we reasoned that preparation of truncated mutants close to the C terminus should identify the epitope involved. Mutants were prepared as described in Materials and Methods by introducing premature termination codons into the wild-type M13 construct, mpRT4. The constructs prepared are indicated in Table 2 . The polypeptides induced in E. coli by the mutants were identified by polyacrylamide gel electrophoresis, followed by staining of the gels (Fig. 5A ) and electrophoretic transfer for Western blots against RTMAb8 (Fig. 5B) .
The first mutant, CTRT1, which expresses a polypeptide which lost 130 amino acids from the C terminus, was designed to mimic the 51-kDa polypeptide and, as expected, did not bind RTMAb8. The second mutant, CTRT2, which should express a polypeptide which lost 29 amino acids from Table 2 ) expressed in E. coli after induction with isopropyl-p-D-thiogalactopyranoside analyzed on 7.5% polyacrylamide gels and stained with Kenacid Blue R. The induced polypeptides visible on stained gels when compared with the vector control, mptacl8, are indicated with arrows (the unlabeled track contained mutant RTM5 from Larder et al. [12] isopropyl-3-D-thiogalactopyranoside (15 h) , and extracts were prepared and run on gels for staining and blotting with pooled ascitic fluid for RT MAbs 1 to 7.
FIG. 5. (A) RT C-terminally truncated mutants (constructs shown in
the C terminus of the 66-kDa polypeptide, was prepared because it stops near the second KpnI site used to prepare mpRT5. This mutant polypeptide did not react with RTMAb8, indicating that the epitope lies within 29 amino acids of the C terminus. We prepared a series of mutants which expressed a polypeptide with a decreasing number of amino acids removed from the C terminus at intervals of four to eight amino acids (Table 2 ). These were screened against RTMAb8 and showed that amino acids 531 to 539 form part or all of the epitope. A 15-mer peptide synthesized to cover this region was coupled to thyroglobulin and used coupled or uncoupled in ELISAs to determine whether RTMAb8 would bind to the peptide. Positive control antisera raised to the thyroglobulin-coupled peptide were shown to bind to the uncoupled peptide. In these assays, RTMAb8 did not bind to the peptide, nor did the peptide block the binding of RTMAb8 to RT. These results indicate that a conformational epitope is involved. The RT activities of these mutant polypeptides in E. coli extracts relative to that of the wild-type RT expressed by mpRT4 were determined. It was found that the 51-kDa polypeptide expressed by CTRT1 retained significant activity, although this was only approximately 5% of that of the control 66-kDa polypeptide. With CTRT2, the 65-kDa polypeptide expressed, which lost 29 amino acids from the C terminus, also had reduced RT activity, approximately 30% of that of the control. The remaining mutant polypeptides, with 21 amino acids or less removed from the C terminus, all had high-level RT activity, comparable to wild-type RT. (b) Epitope mapping of RT MAbs 1 to 7. Further truncated mutants were prepared as described in Materials and Methods, and each construct was confirmed by sequencing (Table  3) . When these mutant bacteriophage clones were used to infect E. coli, no induced polypeptides could be identified as stained bands on the gel. However, when these extracts were blotted against individual or pooled RT MAbs 1 to 7, polypeptides expressed by several mutants were detected (Fig. 6) . All of the RT MAbs 1 to 7 reacted with a 37-kDa product present in infected extracts of mutant MTRT11. This 37-kDa polypeptide has 246 amino acids removed from the C terminus of the 66-kDa polypeptide. This (Fig. 2) .
Analysis of the RT activity of the C-terminally truncated mutants proved interesting. The 51-kDa mutant polypeptide constructed to mimic the 51-kDa polypeptide seen in the virus was found to have some RT activity, although it was only 5% of that seen with the 66-kDa construct. This therefore suggests that the 51-kDa polypeptide in the virus should possess some inherent activity. This result differs from that reported by Hansen et al. (8) , who suggested that the 51-kDa polypeptide in the virus lacked RT activity. However, to assay for RT activity, Hansen et al. (8) used an activated-gel analysis method which might miss the lowlevel activity of the 51-kDa polypeptide by denaturing the polypeptide present or because of inherent insensitivity. Studies with the other mutants revealed that up to 21 amino acids could be removed from the C terminus without affecting RT activity, although removal of a further 8 amino acids resulted in considerable loss of activity. This reduction in activity mapped close to the RTMAb8 epitope and may further indicate that a conformational change occurred in this area with the shorter mutant polypeptides. However, this MAb did not neutralize RT activity; this suggests that this C-terminal region does not form part of the RT active sites. Similarly, none of the other RT MAbs neutralized RT activity, and therefore amino acids 230 to 315 from the N terminus are probably not involved with the RT active sites, although in both cases such sites may be inaccessible to the antibodies. Hansen et al. (8) demonstrated that the Cterminal portion of the 66-kDa polypeptide is associated with RNase H activity. Current analysis of our C-terminally truncated mutants for RNase H activity should therefore prove interesting and may help to identify the active sites for the RNase H portion of the enzyme.
Purification of the 66-kDa expressed polypeptide in bacterial extracts with RTMAb8 immunoaffinity columns and purification of the mutant polypeptides with RTMAb3 immunoaffinity columns was achieved. These purification methods will be invaluable in further characterization of the 66-kDa polypeptide and the mutant polypeptides. Such purification is a prerequisite for the detailed study of RNase H activity. In recent work, we have concentrated on largescale purification of the 66-kDa polypeptide with RTMAb8 immunoaffinity columns. This has yielded gram quantities of the purified 66-kDa polypeptide, which is being used in crystallization studies.
